Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
31.12
-1.41 (-4.33%)
At close: Feb 21, 2025, 4:00 PM
31.00
-0.12 (-0.39%)
After-hours: Feb 21, 2025, 7:48 PM EST
Avidity Biosciences Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Avidity Biosciences stock have an average target of 65.8, with a low estimate of 45 and a high estimate of 96. The average target predicts an increase of 111.44% from the current stock price of 31.12.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 21, 2025.
Analyst Ratings
The average analyst rating for Avidity Biosciences stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 6 | 6 | 6 |
| Buy | 4 | 4 | 5 | 5 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $67 | Buy | Reiterates | $67 | +115.30% | Jan 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +131.36% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | +131.36% | Dec 20, 2024 |
| RBC Capital | RBC Capital | Buy Initiates $67 | Buy | Initiates | $67 | +115.30% | Nov 26, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $65 | Strong Buy | Maintains | $65 | +108.87% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
8.75M
from 9.56M
Decreased by -8.44%
Revenue Next Year
7.18M
from 8.75M
Decreased by -17.95%
EPS This Year
-2.90
from -2.91
EPS Next Year
-3.34
from -2.90
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 13.4M | 20.7M | 76.1M | |||
| Avg | 8.8M | 7.2M | 24.1M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 40.6% | 136.3% | 959.9% | |||
| Avg | -8.4% | -17.9% | 235.7% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.71 | -2.60 | -2.37 | |||
| Avg | -2.90 | -3.34 | -3.66 | |||
| Low | -3.00 | -4.45 | -4.72 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.